US 12,285,498 B2
Pharmaceutical composition with nanoparticle-based drug delivery combined with non-invasive radiographic monitoring model
Joe G Assouline, Coralville, IA (US); and Sean K. Sweeney, Coralville, IA (US)
Assigned to NANOMEDTRIX, LLC, Coralville, IA (US)
Filed by NANOMEDTRIX, LLC, Coralville, IA (US)
Filed on Aug. 21, 2024, as Appl. No. 18/811,352.
Application 18/811,352 is a continuation of application No. 18/456,300, filed on Aug. 25, 2023, granted, now 12,102,693.
Prior Publication US 2025/0064987 A1, Feb. 27, 2025
Int. Cl. A61K 9/51 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61K 31/337 (2006.01); A61K 31/407 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); A61K 49/00 (2006.01); A61K 49/08 (2006.01); A61K 49/22 (2006.01); A61P 35/00 (2006.01)
CPC A61K 49/0002 (2013.01) [A61K 9/0053 (2013.01); A61K 9/5115 (2013.01); A61K 31/337 (2013.01); A61K 31/407 (2013.01); A61K 31/658 (2023.05); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 49/0093 (2013.01); A61K 49/085 (2013.01); A61K 49/225 (2013.01); A61P 35/00 (2018.01)] 17 Claims
 
1. A method of treatment of a tumor comprising the steps of:
administering to a patient a first pharmaceutical composition and a second pharmaceutical composition;
wherein the first pharmaceutical composition comprises a mesoporous silica nanoparticle (“MSN”), a first bioactive agent comprising a first chemotherapeutic agent loaded into the MSN, a first coating encapsulating the surface of the MSN, and a targeting peptide or an amino acid covalently linked to the MSN;
wherein the second pharmaceutical composition comprises an MSN, a second bioactive agent comprising a second chemotherapeutic agent loaded into the MSN, a second coating encapsulating the MSN, and a targeting peptide or an amino acid covalently linked to the MSN; and
wherein the first bioactive agent is distinct from the second bioactive agent and the first chemotherapeutic agent and the second chemotherapeutic agent are chemically incompatible such that interaction between the two results in a reduction in effectiveness; and wherein the first pharmaceutical composition comprising the first chemotherapeutic agent and the second pharmaceutical composition comprising the second chemotherapeutic agent act upon a tumor sequentially or substantially concurrently without chemically interacting with each other.